102 related articles for article (PubMed ID: 27790952)
1. Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
Reichel D; Lee MJ; Lee W; Kim KB; Bae Y
Ther Deliv; 2016 Oct; 7(10):665-681. PubMed ID: 27790952
[TBL] [Abstract][Full Text] [Related]
2. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
3. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
5. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
6. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
[TBL] [Abstract][Full Text] [Related]
7. Effects of Organic Acids on Drug Release From Ternary Polypeptide Nanoparticles Entrapping Carfilzomib.
Jackson S; Agbana P; Kim KB; Bae Y
J Pharm Sci; 2022 Apr; 111(4):1172-1177. PubMed ID: 34551351
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
9. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
10. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
[TBL] [Abstract][Full Text] [Related]
12. Development of polymeric irinotecan nanoparticles using a novel lactone preservation strategy.
Poudel BK; Gupta B; Ramasamy T; Thapa RK; Youn YS; Choi HG; Yong CS; Kim JO
Int J Pharm; 2016 Oct; 512(1):75-86. PubMed ID: 27558884
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
14. Molecular encapsulator on the surface of magnetic nanoparticles. Controlled drug release from calcium Ferrite/Cyclodextrin-tethered polymer hybrid.
Ramasamy S; Samathanam B; Reuther H; Adyanpuram MNMS; Enoch IVMV; Potzger K
Colloids Surf B Biointerfaces; 2018 Jan; 161():347-355. PubMed ID: 29100128
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
Wang Z; Yang J; Kirk C; Fang Y; Alsina M; Badros A; Papadopoulos K; Wong A; Woo T; Bomba D; Li J; Infante JR
Drug Metab Dispos; 2013 Jan; 41(1):230-7. PubMed ID: 23118326
[TBL] [Abstract][Full Text] [Related]
16. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
17. Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
Federspiel JD; Codreanu SG; Goyal S; Albertolle ME; Lowe E; Teague J; Wong H; Guengerich FP; Liebler DC
Mol Cell Proteomics; 2016 Oct; 15(10):3233-3242. PubMed ID: 27503896
[TBL] [Abstract][Full Text] [Related]
18. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib reverses pulmonary arterial hypertension.
Wang X; Ibrahim YF; Das D; Zungu-Edmondson M; Shults NV; Suzuki YJ
Cardiovasc Res; 2016 May; 110(2):188-99. PubMed ID: 26952044
[TBL] [Abstract][Full Text] [Related]
20. Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
Chen-Scarabelli C; Corsetti G; Pasini E; Dioguardi FS; Sahni G; Narula J; Gavazzoni M; Patel H; Saravolatz L; Knight R; Raddino R; Scarabelli TM
EBioMedicine; 2017 Jul; 21():206-212. PubMed ID: 28587834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
